<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620902</url>
  </required_header>
  <id_info>
    <org_study_id>15-4-100</org_study_id>
    <nct_id>NCT04620902</nct_id>
  </id_info>
  <brief_title>Detection of AD Biomarkers in Tear Fluid</brief_title>
  <acronym>SmartTears</acronym>
  <official_title>Detection of AD Biomarkers in Tear Fluid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Detection of AD biomarkers in tear fluid&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">January 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Level of AD biomarkers in tear fluid</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">69</enrollment>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Dementia</arm_group_label>
    <description>Dementia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI</arm_group_label>
    <description>Mild cognitive impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCD</arm_group_label>
    <description>Subjective cognitive decline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HC</arm_group_label>
    <description>Cognitively healthy control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tear sampling</intervention_name>
    <description>Tear sampling using Schirmer's strips</description>
    <arm_group_label>Dementia</arm_group_label>
    <arm_group_label>HC</arm_group_label>
    <arm_group_label>MCI</arm_group_label>
    <arm_group_label>SCD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 60 patients and nine cognitively healthy age-matched controls (HC) were enrolled&#xD;
        in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  . Inclusion criteria were an MMSE score â‰¥ 20 and a CDR score from 0 to 1, thereby&#xD;
             including patients across the whole clinical spectrum (i.e. from subjective cognitive&#xD;
             disorder to (mild) dementia).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria at baseline were neurological diseases (such as Normal Pressure&#xD;
             Hydrocephalus, Morbus Huntington, brain tumor, epilepsy, encephalitis, recent&#xD;
             Transient Ischemic Attack (TIA) or cerebrovascular accident (CVA) (&lt; 2 years), or&#xD;
             TIA/CVA with concurrent (within three months) cognitive decline) and a history of&#xD;
             psychiatric disorders (such as schizophrenia, bipolar disorder or psychotic problems,&#xD;
             current major depressive disorder (within 12 months), or alcohol abuse).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academic Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

